

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA

**Adalimumab, etanercept and ustekinumab for treating plaque psoriasis
in children and young people**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The follow potential equalities issues were identified during the scoping process:

- children and young people with psoriasis may have inflammatory bowel disease or juvenile idiopathic arthritis. The NICE team note that some of these people may be classified as disabled.
- children and young people are more likely to prefer oral medication compared with injections. The NICE team note that this issue does not relate to protected characteristics, as defined by the Equalities Act, and so is not considered an equality issue.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential

equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director (name): ...Melinda Goodall.....

Date: 12/04/2016